Newcastle Launches the UK’s First National Centre for Neurotechnology and Neurorestoration

United Kingdom - 03 Dec 2025: Experts from Newcastle Hospitals, in collaboration with Newcastle University, have established the National Centre for Neurotechnology and Neurorestoration, the UK’s first dedicated facility for clinical trials involving advanced neurotechnologies.

The new centre will support the development, testing, and implementation of cutting-edge technologies designed to better understand the brain, restore lost function, and improve health outcomes for people living with neurological conditions.

The facility will lead the country’s clinical research into pioneering implanted devices, including technologies placed in or near the brain and nervous system. This work will centre on brain–computer interfaces (BCIs), neurostimulators, and other next-generation devices aimed at improving movement, sensation, mood, and cognitive function.

By specialising in these state-of-the-art approaches, the centre aims to expand treatment options for a wide range of disabling neurological disorders.

Alongside clinical trials, the centre will facilitate research aimed at advancing scientific knowledge of the human brain. Its experts will help accelerate the development of future neurotechnologies and ensure that patients can safely access the latest trial opportunities.

The centre will act as a national hub for academics and industry partners, both in the UK and internationally, providing regulatory, clinical, and scientific support to rapidly and safely progress neurotechnology research.

In an official publication by Newcastle Hospitals, Mr Akbar Hussain, clinical director of the new centre and consultant neurosurgeon at Newcastle Hospitals, said the facility comes at a pivotal moment in neuroscience:

“Through the rapid rise of modern neurotechnologies and advances in artificial intelligence, we are entering a new era in treating disorders of the brain and nervous system.
The centre will allow us to strengthen and grow our capacity and skills to meet demand and will mean we can pave the way for a future standard of care in neurological disorders, allowing more life-changing treatments to be brought to patients.”

Dr Luke Bashford, scientific director, added:

“The neurotechnology device industry is burgeoning and seeking expert healthcare partners, and the scientific community is entering a period of unprecedented scale of access to the human brain for research.
The centre will provide all stakeholders with the academic, regulatory and clinical support to ensure that there are no delays to performing the full spectrum of UK neurotechnology work.”

Overall, the study represents an important early step in advancing brain–computer interface research, laying the groundwork for future developments in neurotechnology and patient care.